Double-Stapled Peptide Scan Yields Potent Fusion Inhibitors of Respiratory Syncytial Virus.
Double-stapled peptides just scored a win against respiratory syncytial virus (RSV). Pidoux and team found three new double-stapled peptides—3/4i, 3/4m, and 4/4g—that block RSV’s fusion process. These aren’t just any peptides; they’re derived from the virus’s own F heptad repeat region and stay active even when the virus mutates to dodge typical small-molecule fusion inhibitors.
J Med Chem
by Pidoux N, Roh L, Nicolet N et al.
“Double-Stapled Peptide Scan Yields Potent Fusion Inhibitors of Respiratory Syncytial Virus. Pidoux N(1), Roh L(1), Nicolet N(1), Marti R(2), Le Rouzic A(3), Prompt C(3), Fix J(3), Duquerroy S(4), Rey F(4)(5), Rameix-Welti MA(6), Keck M(7), Barbe P(7), Garcin D(8), Mottet-Osman G(8), Larcher T(9), Galloux M(3), Nyanguile O(1). Author information: (1)HES-SO Valais-Wallis, Institute of Life Sciences, HES-SO University of Applied Sciences Western and Arts Switzerland, rue de l'Industrie 19, Sion 1950, Switzerland. (2)Institute of Chemical Technology, Haute école d'ingénierie et d'architecture Fribourg, HES-SO University of Applied Sciences and Arts Western Switzerland, Fribourg 1700, Switzerland. (3)VIM, INRAE, Domaine de Vilvert, Jouy-en-Josas 78350, France. (4)Université Paris Saclay, Structural Virology Unit, Institut Pasteur, 28 rue du Dr Roux, Paris 75015, France. (5)Université Paris-Saclay, Faculté des Sciences, Orsay 91400, France. (6)Institut Pasteur, Université Paris-Saclay, Université de Versailles St. Quentin, Université Paris Cité, Assistance Publique des Hôpitaux de Paris, Hôpital Ambroise Paré, M3P, UMR 1173 (2I), INSERM, Centre National de Référence Virus des Infections Respiratoires (CNR VIR), Paris 75015, France. (7)Université Paris-Saclay, CEA, INRAE, Département Médicaments et Technologies pour la Santé (DMTS), SIMoS, Gif-sur-Yvette 91191, France. (8)Department of Microbiology and Molecular Medicine, University of Geneva School of Medicine, CMU, Geneva 1211, Switzerland. (9)INRAE, Oniris, UMR 703 Apex, Nantes 44307, France. Respiratory syncytial virus infection (RSV) is a major global health concern, particularly in infants and elderly populations. In this work, we have screened and identified 3 double-stapled peptides derived from a minimal domain of the RSV F heptad repeat, namely 3/4i, 3/4m, and 4/4g, which are potent inhibitors of RSV fusion and remain active against viral escape mutants resistant to small-molecule fusion inhibitors. Our structural activity relationship (SAR) analysis demonstrates that combining a limited set of staples is sufficient to achieve high antiviral potency. X-ray crystallography revealed that the enhanced potency of 3/4i and 3/4m primarily arises from strong hydrophobic interactions between the N-terminal staple and the trimeric HR1 coiled coil of RSV F. In vivo pharmacokinetic, imaging, and feasibility studies in RSV-infected Balb/c mice further support intranasal administration as a promising route for delivering these stapled peptides to the lung, highlighting their potential as therapeutics against RSV.”
Here’s why this matters: RSV is brutal for infants and older adults. There’s a constant need for new tools that can work even when the virus evolves. Double-stapled peptides bring some serious advantages to the table:
They’re stable—those “staples” are hydrocarbon bridges that lock the peptide into a potent, active shape.
They keep working against viral mutants that escape other treatments.
X-ray crystallography confirmed how these peptides latch onto RSV’s fusion machinery, with extra punch coming from hydrophobic interactions at the N-terminal staple.
The research didn’t stop at test tubes. In vivo work in RSV-infected mice showed these stapled peptides can be delivered straight to the lungs via intranasal dosing. That’s practical. It means the compounds reach the target tissue without getting mangled by the bloodstream’s usual peptide-chopping enzymes.
Key takeaway: Double-stapled peptides are shaping up as a versatile platform for antiviral research, not just for RSV but possibly for other fusion-driven viruses. If you’re tracking innovation in peptide research, this is one to watch.
Want to see which vendors are offering research-grade peptides? Check out the vendor directory for sourcing options. No hype—just another example of what’s possible when the research community pushes peptide science forward.
Related Reading
EDTA enhances antimicrobial activity of PR-39 and Protegrin-1 antimicrobial peptides against carbapenem-resistant Pseudomonas aeruginosa in serum.
News · Pharmacol RepEvaluation of the safety profile of glucagon-like peptide-1 receptor agonists: a focus on thyroid cancer-related adverse events by using the European pharmacovigilance database.
News · J Biomol Struct DynmePTL: miRNA-encoded peptides identification using multi-source feature transformation and ensemble learning.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.